Form 4: Teladoc Health's Chief Medical Officer, Vidya Raman-Tangella, Executes Stock Transactions
SEC Form 4
Vidya Raman-Tangella, Chief Medical Officer of Teladoc Health, reports transactions involving common stock, performance stock units, and restricted stock units.
Summary
- Vidya Raman-Tangella, the Chief Medical Officer of Teladoc Health, filed a Form 4 detailing changes in beneficial ownership.
- On May 31, 2024, Raman-Tangella acquired 792 shares of common stock through the conversion of performance stock units and 2,325 shares through the conversion of restricted stock units.
- Also on May 31, 2024, she sold 3,407 shares of common stock at a price of $11.21 per share.
- On June 3, 2024, she sold 1,122 shares at $11.157 per share to cover tax obligations related to vesting.
- On June 4, 2024, she sold 468 shares at $11.04 per share.
- These transactions were executed under a Rule 10b5-1 trading plan adopted on March 1, 2024.
- Following these transactions, Raman-Tangella directly owns 27,280 shares of common stock and holds 5,548 performance stock units and 16,277 restricted stock units.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the transactions appear to be part of a pre-planned trading strategy under Rule 10b5-1. The sales are offset by the acquisition of shares through unit conversions.
Industry Context
Insider transactions are routinely monitored by investors to gauge executive sentiment regarding the company's prospects. While sales can be driven by various personal financial planning reasons, significant or sustained selling activity may raise concerns.
Stakeholder Impact
- Shareholders may interpret insider selling as a lack of confidence in the company's future performance, potentially leading to negative sentiment.
Key Dates
| Date | Description |
|---|---|
| March 1, 2024 | Reporting person adopted a Rule 10b5-1 trading plan |
| March 3, 2023 | Reporting person was granted 27,902 restricted stock units, vesting one-third on March 1, 2024, with the remainder vesting in eight substantially equal quarterly installments thereafter. |
| May 31, 2024 | Acquisition of 792 shares via performance stock units conversion |
| May 31, 2024 | Acquisition of 2,325 shares via restricted stock units conversion |
| May 31, 2024 | Sale of 3,407 shares at $11.21 |
| June 3, 2024 | Sale of 1,122 shares at $11.157 |
| June 4, 2024 | Sale of 468 shares at $11.04 |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.